CMS Office of Patient Advocacy
This article was originally published in The Gray Sheet
Executive Summary
Agency is considering creating an office that would interact with healthcare consumers and disease advocacy groups to inform Medicare and Medicaid policy decisions. The office would resemble FDA's Office of Special Health Issues, which responds to patients' questions on HIV/AIDS, cancer, diabetes therapies and clinical trial enrollment. In addition, OSHI aids policymaking for "special populations," a role CMS also may adopt...
You may also be interested in...
CMS-Supported Clinical Data Collection Worth The Cost – Tunis
CMS will seek public comments early this year on criteria for deciding which national coverage policies should include data collection requirements
At-Home Health Testing Demand Is High Post-Pandemic, But So Are Barriers To Development And Use
At the recent Precision Med-Tri Con conference, laboratory experts traded views on the expansion of at-home testing for disease diagnosis and personalized health insights. While strong consumer demand spells opportunity, there are significant concerns about the accuracy and reliability of home-testing platforms, misuse, accessibility, and lack of health literacy.
Simplified Clinical Trial Transparency Rules To Go Live In The EU In June
A new version of the EU Clinical Trials Information System’s public portal will integrate the functionalities of the streamlined transparency rules.